CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma

Conditions:   Locally Advanced Malignant Solid Neoplasm;   Metastatic Pancreatic Adenocarcinoma;   Stage IV Pancreatic Cancer AJCC v8;   Unresectable Malignant Solid Neoplasm Interventions:   Biological: Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949;   Drug: VLP-encapsulated TLR9 Agonist CMP-001 Sponsors:   University of Southern California;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials